NASDAQ:CNSP - CNS Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CNS Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.10 +0.02 (+0.49 %) (As of 12/6/2019 01:20 PM ET) Add Compare Today's Range$4.01Now: $4.10▼$4.1150-Day Range N/A52-Week Range$3.86Now: $4.10▼$5.69Volume1,402 shsAverage Volume132,917 shsMarket Capitalization$64.42 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. The company was founded in 2017 and is based in Houston, Texas. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNSP Previous Symbol CUSIPN/A CIKN/A Webhttp://cnspharma.com/ Phone800-946-9185Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares15,712,000Market Cap$64.42 million Next Earnings DateN/A OptionableNot Optionable Receive CNSP News and Ratings via Email Sign-up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CNSP Rates by TradingView CNS Pharmaceuticals (NASDAQ:CNSP) Frequently Asked Questions What is CNS Pharmaceuticals' stock symbol? CNS Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNSP." What is the consensus analysts' recommendation for CNS Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CNS Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CNS Pharmaceuticals. Has CNS Pharmaceuticals been receiving favorable news coverage? Media headlines about CNSP stock have trended neutral recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CNS Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for CNS Pharmaceuticals. Who are some of CNS Pharmaceuticals' key competitors? Some companies that are related to CNS Pharmaceuticals include Fulcrum Therapeutics (FULC), GlycoMimetics (GLYC), MannKind (MNKD), Calithera Biosciences (CALA), Neptune Wellness Solutions (NEPT), Xeris Pharmaceuticals (XERS), Minerva Neurosciences (NERV), Theratechnologies (THERF), Syndax Pharmaceuticals (SNDX), Aeglea Bio Therapeutics (AGLE), BIOFRONTERA AG/ADR (BFRA), Chiasma (CHMA), NuCana (NCNA), Aquestive Therapeutics (AQST) and Hookipa Pharma (HOOK). What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Editas Medicine (EDIT), DURECT (DRRX), Diffusion Pharmaceuticals (DFFN), Curis (CRIS), Clovis Oncology (CLVS), BIOLINERX LTD/S (BLRX), Bed Bath & Beyond (BBBY), Air Transport Services Group (ATSG), Amarin (AMRN) and Advanced Micro Devices (AMD). When did CNS Pharmaceuticals IPO? (CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO. When does the company's quiet period expire? CNS Pharmaceuticals' quiet period expires on Wednesday, December 18th. CNS Pharmaceuticals had issued 2,125,000 shares in its IPO on November 8th. The total size of the offering was $8,500,000 based on an initial share price of $4.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is CNS Pharmaceuticals' stock price today? One share of CNSP stock can currently be purchased for approximately $4.10. How big of a company is CNS Pharmaceuticals? CNS Pharmaceuticals has a market capitalization of $64.42 million. View Additional Information About CNS Pharmaceuticals. What is CNS Pharmaceuticals' official website? The official website for CNS Pharmaceuticals is http://cnspharma.com/. How can I contact CNS Pharmaceuticals? CNS Pharmaceuticals' mailing address is 2100 WEST LOOP SOUTH SUITE 900, HOUSTON TX, 77027. The company can be reached via phone at 800-946-9185 or via email at [email protected] MarketBeat Community Rating for CNS Pharmaceuticals (NASDAQ CNSP)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 8 (Vote Outperform)Underperform Votes: 9 (Vote Underperform)Total Votes: 17MarketBeat's community ratings are surveys of what our community members think about CNS Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNSP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: What Is An Exchange-Traded Fund (ETF)?
